Fusion protein · Immune activation, directed at HPV16 E7 protein (residues 11-20 epitope) · developed by Cue Biopharma
CUE-101 is a fusion protein combining an HLA-A*0201 complex loaded with an HPV16 E7 peptide epitope, a reduced-affinity interleukin-2 variant, and an attenuated IgG1 Fc domain. It binds E7-specific CD8-positive T cells, promoting their activation, expansion and interferon gamma secretion. It is being studied in oropharyngeal squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07172256 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Recruiting | CUE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Oropharyngeal Squamous Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the CUE page.
See CUE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CUE catalysts and pipeline →